Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
| 대상 질환 | Melanoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| 상태 | 완료 |
| 참여자 수 | 26 명 |
| 중재(약물) | Nivolumab |
| 시작일 | 2018년 1월 17일 |
| 완료일 | 2025년 12월 15일 |
| 결과 공개일 | 2026년 6월 16일 |
요약
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Recurrence-free Survival
| Treatment (Nivolumab) | 87.8 percentage of participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)